The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies ...

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

Amgen’s biosimilar formulation is distinct from both the Regeneron patent covering Eylea and from the other biosimilars ... a way to prepare and formulate the active ingredient, aflibercept, in a ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

On March 5, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s entry ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

Earlier this month, the South Korean biosimilar maker secured approval for three other drugs from Europe: Eydenzelt, referencing blockbuster eye disease treatment Eylea; Stoboclo and Osenvelt.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not ...

Lloyd Clark, MD, discusses the use of aflibercept 8 mg in the treatment of retinal vein occlusion. Clinical trial data support the use of higher-dose VEGF inhibition, he said. “I’m very ...

FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases UK market authorization follows successful ...

FYB203, a biosimilar to aflibercept, received UK MHRA approval for multiple retinal conditions and will be marketed as AHZANTIVE. The European Commission approved FYB203 under the names AHZANTIVE and ...